🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — September 08, 2026

The S&P 500 Healthcare sector is flashing a starkly mixed picture: a severe, material cybersecurity incident at Boston Scientific is set to disrupt near-term financials and guidance, while the rest of the filings point to routine corporate activity. The most critical development is Boston Scientific's disclosure of a network outage that will materially impact Q3 and full-year 2026 results, forcing a likely guidance miss and creating significant downside risk for the stock. In contrast, insider activity at Cigna and Moderna is low-materiality and largely neutral, with a CFO tax-withholding sale at Moderna being the only notable transaction. UnitedHealth's upcoming participation at a healthcare conference provides a near-term catalyst for sector sentiment but no new financial data. The overarching theme is one of operational risk (cyber) overwhelming otherwise quiet, routine corporate governance filings. There are no positive period-over-period trends or bullish capital allocation signals in this batch, reinforcing a cautious near-term stance on the sector.

4 high priority 1 medium 5 total filings
· daily

US Earnings Financial Results SEC Filings — September 08, 2026

The 19 filings for the period ending July 31, 2026, reveal a bifurcated market: high-growth tech and industrial companies (Samsara, Dell, Casey's) are delivering strong revenue and profit growth, while many smaller biotech and pre-revenue firms (enGene, MMEX, Braveheart) continue to burn cash with widening losses. A notable theme is the prevalence of 'mixed' sentiment (12 of 19 filings), often driven by non-recurring gains masking underlying operational weakness (e.g., Apnimed, G-III Apparel). Capital allocation is aggressive, with significant M&A (Mission Produce, ABM Industries) and share buybacks (Dell, UiPath, ABM) reshaping balance sheets. Insider trading activity is sparse, but the absence of insider buying in several cash-burning companies is a concern. The most critical development is Dell's 57.7% revenue surge, signaling robust AI-driven demand, contrasted with the gold ETF's 16% NAV decline, reflecting a macro shift away from safe havens. Overall, the data suggests a 'risk-on' environment favoring growth and operational leverage, while punishing companies without clear paths to profitability.

19 high priority 19 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 08, 2026

The 7 filings in this executive compensation digest reveal a landscape dominated by corporate control events and governance restructuring, with limited direct executive pay data. The most critical development is Lantheus Holdings' pending acquisition, which will trigger significant change-of-control payments and delisting, representing a high-materiality event for shareholders. A pattern of shareholder dilution and listing compliance struggles is evident across iPower Inc. and Cayson Acquisition Corp, both seeking shareholder approval for actions that could severely impact equity value. Seagate Technology's proxy provides the most substantive executive compensation data, including a CEO pay ratio and pay-versus-performance disclosure, offering a benchmark for the sector. The remaining filings (Hussman Investment Trust, Richtech Robotics, Baillie Gifford ETF Trust) are lower materiality, focusing on routine governance matters like board elections and fund reclassification. Overall, the period-over-period comparisons are sparse, but the forward-looking data points to a catalyst-rich calendar with several shareholder meetings in late September through November 2026.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 08, 2026

The September 8, 2026, IPO pipeline is dominated by a wave of capital-intensive filings from pre-revenue or early-stage companies, signaling a potential shift in market appetite toward high-risk, high-reward opportunities in deep tech and specialty pharma. The most critical development is Navitas Semiconductor's S-4 for its $232.8 million acquisition of Claros, Inc., a transformative deal that will reshape its capital structure and growth trajectory. A clear period-over-period trend is the heavy reliance on dilutive financing structures, with Ocean Power Technologies, Acurx Pharmaceuticals, and CDT Equity all utilizing best-efforts offerings, at-the-market facilities, or convertible notes, indicating persistent cash burn and a challenging fundraising environment for these issuers. The pipeline lacks broad sector cohesion but clusters around companies with significant operational risks, restated financials, and a history of losses, suggesting a 'show-me' story for investors. The most actionable insight is the divergence in capital allocation: Navitas is deploying M&A for growth, while others are purely raising survival capital, creating a clear quality spectrum within the cohort.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — September 08, 2026

Both filings in this digest are from micro-cap companies facing imminent Nasdaq delisting risks, highlighting a concentrated wave of non-compliance among small-cap biotech and consumer goods firms. Aterian, Inc. received a bid price deficiency notice, compounded by the abrupt termination of its CFO, signaling severe internal turmoil and a high probability of failure to regain compliance. Estrella Immunopharma faces a more acute threat, failing not only the Market Value of Listed Securities (MVLS) test but also alternative equity and net income standards, leaving it with no viable path to compliance. The aggregate picture is one of heightened delisting risk in the micro-cap space, with both companies lacking the financial resources or operational catalysts to reverse their stock price declines. The lack of insider buying or positive forward guidance in either filing reinforces a bearish outlook for their near-term equity value.

2 high priority 2 total filings
· daily

US Executive Officer Management Changes SEC — September 08, 2026

This digest of 50 SEC filings reveals a wave of executive leadership transitions across US equities, with a notable concentration of CFO changes and strategic appointments aimed at driving growth and operational efficiency. A key theme is the appointment of seasoned executives with strong track records in M&A, turnaround, and scaling businesses, such as at Pyxis Oncology, Kura Oncology, and Concentra Group. The data shows a mix of planned successions, like at Adobe and Markel Group, and abrupt departures, such as at TPG Inc. and Better Home & Finance, creating a spectrum of risk and opportunity. Insider activity is limited, but the compensation structures and background of new appointees provide strong signals about company strategy. The most critical developments include the high-profile CEO transition at Adobe, the strategic pivot at Health Catalyst with a new CEO who has a proven exit track record, and the leadership vacuum at TPG Inc. following an unexplained resignation. Portfolio-level patterns indicate a sector-agnostic trend towards appointing leaders with digital transformation, AI, and data analytics expertise, particularly in healthcare and financial services. The overall sentiment is cautiously positive, with many changes signaling a focus on value creation, though several departures without clear succession plans warrant close monitoring.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 08, 2026

The two filings in this stream highlight a deeply distressed corporate landscape in the US, with both companies undergoing Chapter 11 bankruptcy proceedings. Synergy CHC Corp. filed for Chapter 11 on September 4, 2026, triggering a complete board overhaul and appointment of a Chief Restructuring Officer, signaling a likely liquidation or major reorganization. Sangamo Therapeutics, in its first monthly operating report post-petition, reveals a cash burn of $11.2 million in July 2026, with total liabilities of $97.1 million against $16.9 million cash, indicating a precarious liquidity position. Both companies exhibit negative sentiment and high materiality, with no positive forward-looking indicators. The lack of any period-over-period revenue or margin data in these filings suggests a focus on survival rather than operational performance. The sector theme is one of acute financial distress, with governance instability and rapid cash depletion as key risk factors.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 08, 2026

The September 8, 2026 board room changes digest reveals a wave of leadership transitions across US-listed companies, with a notable concentration in the healthcare and technology sectors. CFO changes dominate the officer-level moves, with 10+ companies appointing or transitioning CFOs, often with rich compensation packages signaling strategic importance (e.g., Genpact's $3M signing bonus, Kura Oncology's performance-based RSUs). Several transitions are tied to broader strategic reviews or growth initiatives, such as Xponential Fitness's ongoing strategic alternatives review and Clearway Energy's AI-driven transformation office. While most changes are routine, a few carry heightened significance: Adobe's CEO transition (materiality 8/10), Health Catalyst's new CEO appointment (8/10), and StableCoinX's new CEO (7/10) signal potential strategic pivots. The overall sentiment is predominantly neutral (36/50), with a handful of positive (7) and negative (2) filings, suggesting no systemic distress but a period of active board and executive refreshment. No major period-over-period financial trends were disclosed in these filings, as most are event-driven 8-Ks without financial data.

50 high priority 50 total filings
· daily

USA Insider Trading Pulse — September 08, 2026

This digest of 50 insider trading filings from September 8, 2026, reveals a market characterized by cautious insider selling among mid-cap growth companies, particularly in the Israeli tech sector (Nayax, Global-E Online), contrasted with strong insider buying at select value and turnaround plays (Uber, OppFi, Comscore, SCHMID Group). The most significant capital market signal is the aggressive activity by Saba Capital Management, which is actively rotating out of BlackRock ESG Capital Allocation Term Trust ($3.2M sale) while accumulating positions in closed-end funds like Ellsworth Growth & Income Fund and Gabelli Healthcare & WellnessRx Trust, suggesting a targeted activist or arbitrage strategy. Insider award filings dominated the day, with 28 of 50 filings being non-cash compensation events (RSUs, stock options, dividend equivalents), which are neutral signals. However, the concentrated insider buying by CEOs at OppFi and Comscore, both trading at low absolute prices, indicates management conviction in undervalued assets. The data shows no significant period-over-period revenue or margin trends across the portfolio, as the filings are transaction-focused, but the insider activity patterns point to a bifurcated market where insiders are buying deeply discounted names and selling into strength in growth tech.

46 high priority 4 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 08, 2026

The US M&A landscape is bifurcated between high-conviction, strategic acquisitions in industrial and defense tech and the ongoing, high-risk search for targets by cash-rich SPACs. A clear theme emerges of capital flowing into energy infrastructure (nuclear, power solutions) and autonomous systems, with acquisitions like Meshflow/HGP ($921M EV) and AEVEX/BlackSea signaling a premium on specialized technology. Conversely, the SPAC sector shows stress, with Cayson Acquisition's deal termination highlighting execution risk, while Andretti and B&R Technology remain in limbo. Period-over-period data reveals strong operational performance at acquired targets, such as Cat Pumps' 35%+ EBITDA margins and GTS's 36% YoY revenue growth, justifying premium valuations. However, the data also flags significant risk at International Stem Cell, where post-divestiture revenues collapsed to just $296K, and at Medalist Diversified REIT, which is effectively liquidating its asset base. The most critical development is the $800M+ nuclear tech deal, which positions the combined entity for massive government and AI-driven data center demand, while the Solaris acquisition of Omega Foundation Services signals a strategic pivot into the high-growth data center EPC market.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 08, 2026

The overnight filing cycle reveals a market bifurcated between aggressive corporate restructuring and cautious capital management. The most significant development is the $3.9 billion reverse merger between WaFd and EverBank, creating a regional banking powerhouse with projected 29% EPS accretion for WaFd shareholders, though the fixed exchange ratio (59.2% to EverBank) signals a control premium. Concurrently, a wave of dilutive capital raises is sweeping through micro-cap and pre-revenue companies: Ocean Power Technologies (OPTT) is conducting a best-efforts offering with no minimum, Vivos Therapeutics is executing a 52% dilutive debt-to-equity swap, and Indaptus Therapeutics has opened a $100 million ATM facility. On the positive side, Circle Internet Group's acquisition of Tazapay for its stablecoin infrastructure and Belite Bio's NDA submission in Japan under the Sakigake designation represent high-conviction growth plays. The period-over-period data from Holtec Nuclear shows a 5.8% revenue decline but a swing to profitability, while AMC Networks' $120 million settlement forced a 32% cut to its free cash flow guidance, highlighting the financial drag from legacy litigation. Insider activity is sparse but notable: United Microelectronics Corp's CFO executed a large, simultaneous acquisition and disposition of 1 million shares, a neutral signal that warrants monitoring for future intent. The overall theme is one of portfolio cleansing—companies are aggressively addressing balance sheet issues, settling legal overhangs, and positioning for strategic shifts, creating both deep value traps and asymmetric upside opportunities for discerning investors.

15 high priority 35 medium 50 total filings
· daily

Global High-Priority Regulatory Events — September 07, 2026

The September 7, 2026, filing batch reveals a concentrated wave of corporate distress and restructuring activity in the Indian market, with 5 of 11 filings directly related to insolvency proceedings under the IBC. The most critical development is a fresh default by **Infrastructure Leasing & Financial Services Limited (IL&FS)** on a USAID-guaranteed loan, underscoring the lingering systemic risk from its massive ₹18,567.53 crore debt pile, of which only 13% has been discharged. This is compounded by a significant procedural milestone at **Sun Granite Export Ltd**, where the Committee of Creditors has appointed a Resolution Professional, signaling an active and high-stakes CIRP. A notable pattern is the emergence of a complex, multi-entity merger scheme involving **Lodha Developers Limited** absorbing **Roselabs Finance** and **National Standard (India) Limited**, which, while procedural, represents a significant corporate reorganization. The overall sentiment is heavily negative, driven by defaults and insolvencies, with a materiality score of 9/10 for the two default events. The data shows no period-over-period revenue or margin trends, as the filings are event-driven rather than financial performance updates, but the sheer volume of insolvency-related filings (5) points to a potential acceleration in corporate stress resolution, likely impacting credit markets and investor sentiment toward Indian mid-cap and stressed assets.

11 high priority 11 total filings
· daily

Defense Manufacturing Contracts — September 05, 2026

This digest covers a single, high-value civilian space contract: a $660 million firm-fixed-price award from NASA to Blue Origin, LLC for the Mars Sample Return mission. The contract is entirely civilian (NASA), with no defense-related obligations, and represents a significant competitive win for Blue Origin in deep-space exploration. The highest-conviction signal is the bullish competitive moat implied by Blue Origin winning a full-and-open competition against major primes, though the high-risk fixed-price structure and lack of outlayed funds present execution risk. Key watch items include NASA budget stability for the Mars Sample Return program and Blue Origin's milestone performance under fixed-price terms.

1 total filings
· daily

DHS Homeland Security Contracts — September 05, 2026

This digest covers a single DHS contract awarded to PAE Professional Services LLC (a subsidiary of Amentum Holdings Inc.) valued at $224.5 million in total obligation, with no defense-related exposure. The contract, a firm-fixed-price award from USCIS for Application Support Center operations, carries a neutral signal due to its competitive nature and stable civilian agency funding, but execution risk is elevated given the fixed-price structure and only $59.1 million outlayed against the full obligation. The highest-conviction signal is the potential underperformance or delayed funding, which warrants monitoring for margin pressure on Amentum. Key risks include high pricing risk from the fixed-price contract and uncertainty around contract modifications beyond the September 2023 end date.

1 total filings
· daily

New Federal Contractors — September 05, 2026

This digest covers four contracts totaling $1.49 billion, with only one defense-related award (25% of total) and three civilian contracts. The dominant theme is NASA's deep-space exploration investment, led by a $660 million fixed-price contract to Blue Origin for Mars Sample Return, which is the highest-conviction signal. However, execution risk is elevated due to the fixed-price structure and no initial funding outlay. Civilian contracts from GSA, DHS, and GSA for IT and logistics services are neutral, with legacy or maturing periods limiting forward revenue visibility. Key risk is the lack of funded milestones on the Blue Origin contract, which could delay or reduce scope.

4 total filings
· daily

Significant Contract Modifications ($10M+) — September 05, 2026

This digest covers $1.49 billion in total obligations across four contracts, with only one defense-related award (25% defense/civilian split). The dominant theme is civilian agency spending on deep-space exploration, IT services, and logistics, led by a $660 million Blue Origin NASA contract for Mars Sample Return—the highest-conviction signal. However, three of four contracts carry high pricing risk (fixed-price), and the aggregate signal strength is moderate (5.5/10). Key risk: Blue Origin’s fixed-price structure and zero funds outlayed to date create execution uncertainty, while legacy contracts from GDIT and PAE/Amentum offer limited forward revenue visibility.

4 total filings
· daily

Contract Deobligations Alert — September 05, 2026

The September 5, 2026 contract deobligations digest totals $1.49 billion across four awards, with a 25% defense-related mix (1 of 4 contracts). The dominant theme is civilian space and services, led by a $660 million NASA award to Blue Origin for Mars Sample Return, which is the highest-conviction signal (bullish, 7/10) but carries high execution risk due to its fixed-price structure and no outlayed funds. Other awards include a legacy GDIT cost-plus contract for NAVAIR engineering, a PAE (Amentum) fixed-price USCIS contract with potential underperformance, and a GSA small business win for pharmaceutical logistics. Key watch items include NASA budget risks for Mars Sample Return, option exercises on the GSA contract, and the maturing GDIT contract's recompete potential.

4 total filings
· daily

Contract Option Exercises — September 05, 2026

This digest covers $1.487 billion in contract obligations from September 5, 2026, with a 1/4 defense ratio and an average signal strength of 5.5/10. The dominant theme is non-defense space and civilian services, led by a $660 million NASA award to Blue Origin for Mars Sample Return that carries a 7/10 bullish signal but high execution risk due to firm-fixed-price structure and zero funds outlayed. A $440 million GDIT legacy NAVAIR cost-plus contract (awarded 2017) offers low-margin stability but limited forward visibility. A $224.5 million Amentum/PAE USCIS application support contract poses margin risk under fixed-price terms with only 26% funds outlayed. The highest-conviction signal is Blue Origin’s competitive win in deep-space exploration, but the primary risk is NASA budget cuts threatening Mars Sample Return funding.

4 total filings
· daily

Federal Professional Services Contracts — September 05, 2026

The single contract in this period, a $440.5M obligated cost-plus award fee delivery order to General Dynamics Information Technology (GDIT) from GSA for NAVAIR CSM engineering services, represents a legacy award with limited forward-looking investment impact. While the contract is entirely defense-related and signals stable revenue for GDIT through its 2021-2022 end dates, the low outlay ($33M) relative to total value suggests execution is in early stages. The neutral signal strength and low materiality score indicate this is not a near-term catalyst for General Dynamics (GD). The primary risk is the contract's maturity, with no clear follow-on or re-compete data provided, creating a revenue gap risk for GDIT's defense electronics and systems integration segment.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — September 05, 2026

In the single contract recorded for September 05, 2026, the Department of Homeland Security (DHS) awarded Amentum Holdings Inc.'s subsidiary, PAE Professional Services LLC, a $224.5 million obligation under a $556.6 million firm-fixed-price contract for USCIS Application Support Center operations. This is a purely civilian award with no defense-related contracts in the stream, underscoring the non-defense budget environment. The contract shows a neutral signal with high execution risk due to the fixed-price structure and only $59.1 million outlayed against the total obligation, suggesting potential underperformance or delayed funding. The key watch item is the contract's September 2023 end date, which has already passed, raising questions about extensions or recompetes that could impact Amentum's revenue stability.

1 total filings